These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 32468087)

  • 1. Nangibotide in patients with septic shock: a Phase 2a randomized controlled clinical trial.
    François B; Wittebole X; Ferrer R; Mira JP; Dugernier T; Gibot S; Derive M; Olivier A; Cuvier V; Witte S; Pickkers P; Vandenhende F; Garaud JJ; Sánchez M; Salcedo-Magguilli M; Laterre PF
    Intensive Care Med; 2020 Jul; 46(7):1425-1437. PubMed ID: 32468087
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prospective evaluation of the efficacy, safety, and optimal biomarker enrichment strategy for nangibotide, a TREM-1 inhibitor, in patients with septic shock (ASTONISH): a double-blind, randomised, controlled, phase 2b trial.
    François B; Lambden S; Fivez T; Gibot S; Derive M; Grouin JM; Salcedo-Magguilli M; Lemarié J; De Schryver N; Jalkanen V; Hicheur T; Garaud JJ; Cuvier V; Ferrer R; Bestle M; Pettilä V; Mira JP; Bouisse C; Mercier E; Vermassen J; Huberlant V; Vinatier I; Anguel N; Levy M; Laterre PF;
    Lancet Respir Med; 2023 Oct; 11(10):894-904. PubMed ID: 37269870
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of the efficacy and safety of TREM-1 inhibition with nangibotide in patients with COVID-19 receiving respiratory support: the ESSENTIAL randomised, double-blind trial.
    François B; Lambden S; Garaud JJ; Derive M; Grouin JM; Asfar P; Darreau C; Mira JP; Quenot JP; Lemarié J; Mercier E; Lacherade JC; Vinsonneau C; Fivez T; Helms J; Badie J; Levy M; Cuvier V; Salcedo-Magguilli M; Laszlo-Pouvreau AL; Laterre PF; Gibot S;
    EClinicalMedicine; 2023 Jun; 60():102013. PubMed ID: 37350989
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rationale and protocol for the efficacy, safety and tolerability of nangibotide in patients with septic shock (ASTONISH) phase IIb randomised controlled trial.
    Francois B; Lambden S; Gibot S; Derive M; Olivier A; Cuvier V; Witte S; Grouin JM; Garaud JJ; Salcedo-Magguilli M; Levy M; Laterre PF
    BMJ Open; 2021 Jul; 11(7):e042921. PubMed ID: 34233965
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A first-in-man safety and pharmacokinetics study of nangibotide, a new modulator of innate immune response through TREM-1 receptor inhibition.
    Cuvier V; Lorch U; Witte S; Olivier A; Gibot S; Delor I; Garaud JJ; Derive M; Salcedo-Magguilli M
    Br J Clin Pharmacol; 2018 Oct; 84(10):2270-2279. PubMed ID: 29885068
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and tolerability of non-neutralizing adrenomedullin antibody adrecizumab (HAM8101) in septic shock patients: the AdrenOSS-2 phase 2a biomarker-guided trial.
    Laterre PF; Pickkers P; Marx G; Wittebole X; Meziani F; Dugernier T; Huberlant V; Schuerholz T; François B; Lascarrou JB; Beishuizen A; Oueslati H; Contou D; Hoiting O; Lacherade JC; Chousterman B; Pottecher J; Bauer M; Godet T; Karakas M; Helms J; Bergmann A; Zimmermann J; Richter K; Hartmann O; Pars M; Mebazaa A;
    Intensive Care Med; 2021 Nov; 47(11):1284-1294. PubMed ID: 34605947
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selepressin, a novel selective vasopressin V
    Russell JA; Vincent JL; Kjølbye AL; Olsson H; Blemings A; Spapen H; Carl P; Laterre PF; Grundemar L
    Crit Care; 2017 Aug; 21(1):213. PubMed ID: 28807037
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjunctive use of physostigmine salicylate (Anticholium®) in perioperative sepsis and septic shock: study protocol for a randomized, double-blind, placebo-controlled, monocentric trial (Anticholium® per Se).
    Zimmermann JB; Pinder N; Bruckner T; Lehmann M; Motsch J; Brenner T; Hoppe-Tichy T; Swoboda S; Weigand MA; Hofer S
    Trials; 2017 Nov; 18(1):530. PubMed ID: 29126416
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiovascular effects of the nitric oxide synthase inhibitor NG-methyl-L-arginine hydrochloride (546C88) in patients with septic shock: results of a randomized, double-blind, placebo-controlled multicenter study (study no. 144-002).
    Watson D; Grover R; Anzueto A; Lorente J; Smithies M; Bellomo R; Guntupalli K; Grossman S; Donaldson J; Le Gall JR;
    Crit Care Med; 2004 Jan; 32(1):13-20. PubMed ID: 14707555
    [TBL] [Abstract][Full Text] [Related]  

  • 10. p55 Tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock. A randomized controlled multicenter trial. Ro 45-2081 Study Group.
    Abraham E; Glauser MP; Butler T; Garbino J; Gelmont D; Laterre PF; Kudsk K; Bruining HA; Otto C; Tobin E; Zwingelstein C; Lesslauer W; Leighton A
    JAMA; 1997 May; 277(19):1531-8. PubMed ID: 9153367
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lenercept (p55 tumor necrosis factor receptor fusion protein) in severe sepsis and early septic shock: a randomized, double-blind, placebo-controlled, multicenter phase III trial with 1,342 patients.
    Abraham E; Laterre PF; Garbino J; Pingleton S; Butler T; Dugernier T; Margolis B; Kudsk K; Zimmerli W; Anderson P; Reynaert M; Lew D; Lesslauer W; Passe S; Cooper P; Burdeska A; Modi M; Leighton A; Salgo M; Van der Auwera P;
    Crit Care Med; 2001 Mar; 29(3):503-10. PubMed ID: 11373411
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stress doses of hydrocortisone reverse hyperdynamic septic shock: a prospective, randomized, double-blind, single-center study.
    Briegel J; Forst H; Haller M; Schelling G; Kilger E; Kuprat G; Hemmer B; Hummel T; Lenhart A; Heyduck M; Stoll C; Peter K
    Crit Care Med; 1999 Apr; 27(4):723-32. PubMed ID: 10321661
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Decreased organ failure in patients with severe SIRS and septic shock treated with the platelet-activating factor antagonist TCV-309: a prospective, multicenter, double-blind, randomized phase II trial. TCV-309 Septic Shock Study Group.
    Poeze M; Froon AH; Ramsay G; Buurman WA; Greve JW
    Shock; 2000 Oct; 14(4):421-8. PubMed ID: 11049104
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study Group.
    Abraham E; Wunderink R; Silverman H; Perl TM; Nasraway S; Levy H; Bone R; Wenzel RP; Balk R; Allred R
    JAMA; 1995 Mar 22-29; 273(12):934-41. PubMed ID: 7884952
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of high doses of selenium, as sodium selenite, in septic shock: a placebo-controlled, randomized, double-blind, phase II study.
    Forceville X; Laviolle B; Annane D; Vitoux D; Bleichner G; Korach JM; Cantais E; Georges H; Soubirou JL; Combes A; Bellissant E
    Crit Care; 2007; 11(4):R73. PubMed ID: 17617901
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and tolerability of lacosamide as adjunctive therapy for adults with partial-onset seizures: Analysis of data pooled from three randomized, double-blind, placebo-controlled clinical trials.
    Biton V; Gil-Nagel A; Isojarvi J; Doty P; Hebert D; Fountain NB
    Epilepsy Behav; 2015 Nov; 52(Pt A):119-27. PubMed ID: 26414341
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hemodynamic effects of i.v. milrinone lactate in pediatric patients with septic shock. A prospective, double-blinded, randomized, placebo-controlled, interventional study.
    Barton P; Garcia J; Kouatli A; Kitchen L; Zorka A; Lindsay C; Lawless S; Giroir B
    Chest; 1996 May; 109(5):1302-12. PubMed ID: 8625683
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and Safety of Vilobelimab (IFX-1), a Novel Monoclonal Anti-C5a Antibody, in Patients With Early Severe Sepsis or Septic Shock-A Randomized, Placebo-Controlled, Double-Blind, Multicenter, Phase IIa Trial (SCIENS Study).
    Bauer M; Weyland A; Marx G; Bloos F; Weber S; Weiler N; Kluge S; Diers A; Simon TP; Lautenschläger I; Gründling M; Jaschinski U; Simon P; Nierhaus A; Moerer O; Reill L; Jörres A; Guo R; Loeffler M; Reinhart K; Riedemann N
    Crit Care Explor; 2021 Nov; 3(11):e0577. PubMed ID: 34806021
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of stress doses of hydrocortisone on S-100B vs. interleukin-8 and polymorphonuclear elastase levels in human septic shock.
    Mussack T; Briegel J; Schelling G; Biberthaler P; Jochum M
    Clin Chem Lab Med; 2005; 43(3):259-68. PubMed ID: 15843228
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized, double-blind, placebo-controlled trial of granulocyte colony-stimulating factor in patients with septic shock.
    Stephens DP; Thomas JH; Higgins A; Bailey M; Anstey NM; Currie BJ; Cheng AC
    Crit Care Med; 2008 Feb; 36(2):448-54. PubMed ID: 18216600
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.